Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome-Reference-Cited by-同舟云学术

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

Published:2007 Issue:2 Volume:109 Page:265-273
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kantarjian Hagop M.,O'Brien Susan,Shan Jianqin,Aribi Ahmed,Garcia-Manero Guillermo,Jabbour Elias,Ravandi Farhad,Cortes Jorge,Davisson Jan,Issa Jean-Pierre

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference21 articles.

1. Novel therapies for myelodysplastic syndromes

2. . Myelodysplastic syndromes. In: , , eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005: 2144–2154.

3. Proposals for the classification of the myelodysplastic syndromes

4. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997

5. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-03

2. DNA methyltransferase inhibitor exposure–response: Challenges and opportunities;Clinical and Translational Science;2023-06-21

3. Melatonin: A Potential Regulator of DNA Methylation;Antioxidants;2023-05-25

4. Low-dose decitabine for previously untreated acute myeloid leukemia ineligible for intensive chemotherapy aged 65 years or older: a prospective study based on comprehensive geriatric assessment;Therapeutic Advances in Hematology;2023-01

5. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex;British Journal of Cancer;2022-12-08